Skip to main content
Erschienen in: Reactions Weekly 1/2020

01.08.2020 | Case report

Andexanet-α/prothrombin complex concentrate

Thrombotic complications and off-label use: 4 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Barra ME, et al. Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages. Journal of Thrombosis and Haemostasis 18: 1637-1647, No. 7, Jul 2020. Available from: URL: http://doi.org/10.1111/jth.14838 Barra ME, et al. Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages. Journal of Thrombosis and Haemostasis 18: 1637-1647, No. 7, Jul 2020. Available from: URL: http://​doi.​org/​10.​1111/​jth.​14838
Metadaten
Titel
Andexanet-α/prothrombin complex concentrate
Thrombotic complications and off-label use: 4 case reports
Publikationsdatum
01.08.2020
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2020
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-020-81355-7

Weitere Artikel der Ausgabe 1/2020

Reactions Weekly 1/2020 Zur Ausgabe

Case report

Diazepam

Case report

Cotrimoxazole

Case report

Pembrolizumab